Rein Therapeutics Gains Momentum in Quest for New IPF Treatment

AUSTIN, Texas – April 29, 2026 – Rein Therapeutics today announced encouraging progress in its mid-stage clinical trial for LTI-03, a novel drug candidate for idiopathic pulmonary fibrosis (IPF), a relentless and fatal lung disease. The company reported that patient enrollment is accelerating in its Phase 2 RENEW study, a critical step forward in the quest to bring a new therapeutic option to patients with limited choices.

Rein (NASDAQ: RNTX) confirmed that eight patients have been enrolled since the study began in March 2026, with recruitment gaining speed across a growing number of international clinical sites. This progress provides a crucial signal of operational execution for the biopharmaceutical company as it advances a potential first-in-class therapy.

“We are pleased with the progress of our Phase 2 RENEW trial, including our ongoing patient enrollment and the expansion of clinical trial sites across multiple geographies,” said Brian Windsor, Ph.D., Chief Executive Officer of Rein Therapeutics, in a statement. “We believe this continued execution reflects the successful efforts of our clinical teams and investigators, and we remain focused on advancing LTI-03 through development.”

A Disease in Desperate Need of New Options

Idiopathic pulmonary fibrosis is a devastating diagnosis. The disease causes irreversible scarring of the lungs, progressively stiffening the tissue and making it increasingly difficult to breathe. For most patients, the median survival time after diagnosis is less than five years, a prognosis worse than many cancers.

For the past decade, the treatment landscape has been dominated by two oral medications, pirfenidone and nintedanib. While these drugs were breakthroughs, representing the first approved therapies for IPF, they only slow the inevitable decline in lung function. They do not halt the disease, nor do they reverse the existing scar tissue. Furthermore, they are often associated with challenging gastrointestinal side effects that can lead patients to reduce their dose or discontinue treatment altogether.

The field recently saw its first new approval in over a decade with nerandomilast, an inhibitor that offers a new mechanism and a favorable safety profile. However, the fundamental unmet need remains: a therapy that can not only stop the fibrosis but potentially promote healing and regeneration in the damaged lung. This is the ambitious goal that Rein Therapeutics and its competitors are chasing.

The Science of a Dual-Action Approach

Rein’s LTI-03 aims to be more than just another drug that slows the decline. It is built on a different scientific principle, targeting the biology of a protein called Caveolin-1 (Cav1), a key regulator that is depleted in the lungs of IPF patients. LTI-03 is a synthetic peptide, delivered directly to the lungs via a dry powder inhaler, designed to mimic Cav1's protective functions.

What sets LTI-03 apart is its proposed dual-acting mechanism. First, it aims to inhibit the pro-fibrotic signaling pathways—the runaway biological signals that command cells to produce scar tissue. Preclinical studies using human lung tissue showed LTI-03 could suppress these signals, reducing collagen protein levels comparably to existing treatments.

Second, and perhaps more significantly, the drug is designed to protect and preserve alveolar epithelial cells. These cells are critical for gas exchange and are believed to play a vital role in lung repair. By potentially shielding these cells from damage and promoting their survival, LTI-03 may offer a regenerative capacity that current treatments lack. This one-two punch of inhibiting scarring while promoting healing represents a potential paradigm shift in treating IPF.

Data from early-stage human trials has been promising. A Phase 1b study in IPF patients found that inhaled LTI-03 was well-tolerated, with early biomarker data suggesting it was having the intended biological effects, reducing markers of fibrosis while increasing a marker associated with alveolar cell health.

Global Strategy Fuels Clinical Momentum

The RENEW trial is a randomized, placebo-controlled study designed to enroll approximately 120 patients who will receive one of two doses of LTI-03 or a placebo. The primary goal is to measure the drug's effect on forced vital capacity (FVC), the gold-standard measure of lung function used to approve all current IPF therapies. A reduction in the rate of FVC decline is the key benchmark for success.

Rein's announcement highlights a strategic global expansion to accelerate this crucial study. With clinical sites already active in the United States, Australia, and Poland, the company is demonstrating its ability to manage complex international logistics. The planned expansion into the United Kingdom and Germany will further broaden its reach, potentially speeding up the 120-patient enrollment target and ensuring a more diverse patient population, which can strengthen the trial's data.

This global footprint is not just about speed; it's a strategic play. Establishing a network of experienced investigators and clinical sites across continents is a significant undertaking that can pay dividends in later-stage trials and during a potential commercial launch. For a clinical-stage company like Rein, which reported having enough cash to fund operations through September 2025 based on its latest filings, demonstrating this kind of operational momentum is vital for maintaining investor confidence.

Navigating a Challenging and Competitive Field

While the progress is encouraging, the path forward for any IPF drug candidate is fraught with challenges. The history of IPF drug development is littered with high-profile failures in late-stage trials, a stark reminder of the disease's complexity. The competitive landscape is also intensifying, with major pharmaceutical players like Boehringer Ingelheim and Bristol Myers Squibb advancing their own novel candidates through Phase 3 trials.

Companies like Pliant Therapeutics are also exploring innovative targets, such as integrin inhibitors, in mid-stage studies. Success for LTI-03 will depend not only on showing a statistically significant benefit in FVC decline but also on demonstrating a competitive profile in terms of safety, tolerability, and potentially, quality of life improvements.

The accelerated enrollment and global expansion of the RENEW study are positive indicators that Rein Therapeutics is executing its plan effectively. For the thousands of patients and families affected by IPF, every step forward in a clinical trial like this represents a tangible piece of hope for a future with better, more effective treatments.